SEC Form 4	
------------	--

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	en							
hours per response:	0.5							

		<sup>*</sup> Reporting Person <sup>*</sup> YNTHIA L							cker or Trac [ <mark>STE</mark> ]	ding S	Symbol			(Ch	elationship eck all appli X Directo	cable)	ng Per	son(s) to Is: 10% O			
(Last) (First) (Middle) C/O 5960 HEISLEY ROAD						3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015										(give title		Other ( below)			
(Street) MENTOR OH 44060 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>							
(	(			n-Deriv	vative	Se	curit	ies Ac	auired.	Dis	posed o	of. or E	ene	icial	y Owned	1					
1. Title of Security (Instr. 3) 2.			2. Trans Date	Transaction			emed ion Date /Day/Yea	3. 4. Securities Acquired ( Transaction Disposed Of (D) (Instr. 3 Code (Instr. 5)			A) or 5. Amo 4 and Securi Benefi Owned		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A (D	or	Price	Reporter Transact (Instr. 3	tion(s)			(Instr. 4)		
Common	Shares, No	Par Value		11/02	2/2015	5			D		11,05	3	D	(1)		0		D			
		Т	able II -						luired, D s, optior						Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transactio Code (Insti 8)		5. Number 6 n of F		6. Date Exercisa Expiration Date (Month/Day/Year		ble and 7. Title and Amount of		of es ing ve Sec		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactii (Instr. 4)	s Ily	y Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	or Nu of	iount mber ares							
Director Stock Option (right to buy)	\$34.17	11/02/2015			D			2,744	(2)	0	7/31/2018	Commo Shares No Par Value	12	744	(2)	0		D			
Director Stock Option (right to buy)	\$32.36	11/02/2015			D			3,218	(3)	0	8/03/2022	Commo Shares No Pa Value	<b>२</b>	218	(3)	0		D			
Director Stock Option (right to buy)	\$51.53	11/02/2015			D			2,037	(4)	0	8/06/2024	Commo Shares No Pa Value	12	037	(4)	0		D			
Director Stock Option (right to buy)	<b>\$</b> 64.05	11/02/2015			D			4,110	(5)	0	8/31/2025	Commo Shares No Pa Value	1	110	(5)	0		D			
Career Restricted Stock Units	(6)	11/02/2015			D			5,110	(6)		(6)	Commo Shares No Pa Value	5	110	\$0.00	0		D			

## Explanation of Responses:

1. Represents shares of STERIS Corporation ("STERIS") disposed of pursuant to merger of a wholly-owned subsidiary of STERIS plc ("New STERIS") with and into STERIS, with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for ordinary shares of New STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.

2. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 2,744 ordinary shares of New STERIS for \$34.17 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

3. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 3,218 ordinary shares of New STERIS for \$32.36 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

4. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 2,037 ordinary shares of New STERIS for \$51.53 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

5. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 4,110 ordinary shares of New STERIS for \$64.05 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

6. At the effective time of the Merger, each STERIS career restricted stock unit was cancelled and converted to a New STERIS career restricted stock unit, subject to the same terms and conditions that were applicable to the original STERIS career restricted stock unit. These New STERIS career restricted stock units are fully vested and will be settled in New STERIS ordinary shares six months after the cessation of the Director's Board service.

<u>/s/ Dennis P. Patton,</u> <u>Authorized Representative</u> <u>under Power of Attorney</u> \*\* Signature of Reporting Person <u>11/02/2015</u>

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.